Olema Pharmaceuticals Management
Management criteria checks 1/4
Olema Pharmaceuticals' CEO is Sean Bohen, appointed in Sep 2020, has a tenure of 5.33 years. total yearly compensation is $8.13M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $5.95M. The average tenure of the management team and the board of directors is 0.9 years and 5.4 years respectively.
Key information
Sean Bohen
Chief executive officer
US$8.1m
Total compensation
| CEO salary percentage | 8.28% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | less than a year |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution
Nov 19Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market
Apr 08Olema Pharmaceuticals: Interesting But Undifferentiated Data
Feb 17Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Dec 02Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Aug 29
Olema Pharmaceuticals: Still Merits A Small Holding
Jun 17Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
May 11Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$150m |
| Jun 30 2025 | n/a | n/a | -US$142m |
| Mar 31 2025 | n/a | n/a | -US$129m |
| Dec 31 2024 | US$8m | US$673k | -US$129m |
| Sep 30 2024 | n/a | n/a | -US$123m |
| Jun 30 2024 | n/a | n/a | -US$110m |
| Mar 31 2024 | n/a | n/a | -US$99m |
| Dec 31 2023 | US$3m | US$647k | -US$97m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$97m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$6m | US$616k | -US$105m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$95m |
| Mar 31 2022 | n/a | n/a | -US$79m |
| Dec 31 2021 | US$3m | US$595k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$11m | US$178k | -US$24m |
Compensation vs Market: Sean's total compensation ($USD8.13M) is above average for companies of similar size in the US market ($USD5.34M).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
CEO
Sean Bohen (58 yo)
Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$8.13m | 0.30% $ 6.0m | |
| Chief Operating & Financial Officer | 5.6yrs | US$4.28m | 0.31% $ 6.1m | |
| Chief Medical Officer | 4yrs | US$2.98m | 0.0057% $ 112.5k | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | no data | |
| Vice President of Corporate Communications | 1.3yrs | no data | no data | |
| Senior VP & Head of People | no data | no data | no data | |
| Chief Discovery & Non-Clinical Development Officer | 5.6yrs | US$200.00k | 0.90% $ 17.8m | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | less than a year | no data | no data | |
| Senior Vice President of CMC & Supply Chain | less than a year | no data | no data | |
| Senior Vice President of Commercial Strategy & Operations | less than a year | no data | no data |
Experienced Management: OLMA's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$8.13m | 0.30% $ 6.0m | |
| Independent Director | 13yrs | US$257.52k | 0.49% $ 9.7m | |
| Independent Director | 5.4yrs | US$261.12k | 0.11% $ 2.1m | |
| Independent Chairperson of the Board | 5.4yrs | US$280.79k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 4.8yrs | US$11.81k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.2yrs | US$243.52k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$250.06k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$251.07k | no data | |
| Independent Director | 4.8yrs | US$245.79k | 0% $ 0 | |
| Independent Director | 7.5yrs | US$246.79k | 0% $ 0 | |
| Director | 19.4yrs | US$240.79k | 1.09% $ 21.5m |
Experienced Board: OLMA's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 17:28 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Olema Pharmaceuticals, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Naureen Quibria | Capital One Securities, Inc. |
| Zegbeh Jallah | Capital One Securities, Inc. |